Kinetics of serum soluble tumour necrosis factor receptor (TNF‐R) type‐I and type‐II after a single interferon‐alpha (IFN‐α) injection in chronic hepatitis C

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Clinical and Experimental Immunology

• Publication date

  1999-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1365-2249.1999.00992.xPMID 10469062PMCID PMC1905374
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response.

  1998cited by this paper
• Inhibition of tumor necrosis factor and interferon triggered responses by DNA viruses.

  1998cited by this paper
• Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection

  1998cited by this paper
• A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation

  1998cited by this paper
• Relationship Among Hepatic Inflammatory Changes, Circulating Levels of Cytokines, and Response to IFN-α in Chronic Hepatitis C

  1998cited by this paper
• New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine.

  1997cited by this paper
• Antiviral Activity of Tumor Necrosis Factor (TNF) Is Mediated via p55 and p75 TNF Receptors

  1997cited by this paper
• Endogenous interferon-alpha concentration and outcome of interferon treatment in patients with chronic hepatitis C.

  1997cited by this paper
• Expression and modulation of cellular receptors for interferon‐γ, tumour necrosis factor, and Fas on human bone marrow CD34+ cells

  1997cited by this paper
• Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver.

  1997cited by this paper
• Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion.

  1997cited by this paper
• Regulation of expression of transmembrane and soluble 75 kDa tumor necrosis factor receptors by interferon-gamma and granulocyte-macrophage colony-stimulating factor involves transcriptional activation.

  1997cited by this paper
• Effects of interferon‐alpha (IFN‐α) administration on leucocytes in healthy humans

  1997cited by this paper
• Interleukin-10 upregulates tumor necrosis factor receptor type-II (p75) gene expression in endotoxin-stimulated human monocytes.

  1997cited by this paper
• Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections.

  1997cited by this paper
• Recombinant interferon‐α therapy for acute hepatitis B: a randomized, double‐blind, placebo‐controlled trial

  1997cited by this paper
• Tumor necrosis factor alpha inhibits entry of human immunodeficiency virus type 1 into primary human macrophages: a selective role for the 75-kilodalton receptor

  1996cited by this paper
• Tumor necrosis factor α gene expression and the response to interferon in chronic hepatitis C

  1996cited by this paper
• Discordant results from hepatitis C virus genotyping by procedures based on amplification of different genomic regions

  1996cited by this paper
• Hepatitis B virus immunopathogenesis.

  1995cited by this paper
• Trauma causes sustained elevation of soluble tumor necrosis factor receptors.

  1994cited by this paper
• Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activation.

  1994cited by this paper
• Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo.

  1992cited by this paper
• High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia.

  1992cited by this paper
• Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients.

  1991cited by this paper
• Interleukin-6 enhances the expression of tumor necrosis factor receptors on hepatoma cells and hepatocytes.

  1991cited by this paper
• The gene for the type 1 tumor necrosis factor receptor (TNF-R1) is localized on band 12p13

  1991cited by this paper
• The gene for the type II (p75) tumor necrosis factor receptor (TNF-RII) is localized on band 1p36.2–p36.3

  1991cited by this paper
• Practical statistics for medical research

  1990cited by this paper
• Serum tumor necrosis factor levels in patients with infectious disease and septic shock.

  1990cited by this paper
• Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa

  1989cited by this paper
• Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

  1989cited by this paper
• Mechanisms of Action of Interferons

  1989cited by this paper
• Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

  1989cited by this paper
• Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life

  1986cited by this paper
• Mechanism of action of interferon. I. Relationship with viral ribonucleic acid.

  1962cited by this paper

• Soluble inflammatory markers as predictors of liver histological changes in patients with chronic hepatitis C virus infection

  2010cites this paper
• Tumor Necrosis Factor Receptor 1 Expression Is Upregulated in Dendritic Cells in Patients with Chronic HCV Who Respond to Therapy

  2010influential citation
• Soluble inflammatory markers as predictors of hepatocellular damage and therapeutic response in chronic hepatitis C.

  2009cites this paper
• Marcadores inflamatórios solúveis como preditores de alteraçõeshistologicas hepáticas e resposta terapêutica na infecção crônica pelovírus da hepatite C

  2008cites this paper
• Current status of immunomodulatory therapies in HCV infection

  2004cites this paper
• Attacking the Hepatitis C Virus with New Mechanisms of Action: Drugs in the Pipeline

  2004cites this paper
• Effect of alpha 2b interferon on inducement of mIL-2R and treatment of HCV in PBMC from patients with chronic viral hepatitis C.

  2003cites this paper
• Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy.

  2002cites this paper
• SERUM TUMOUR NECROSIS FACTOR-α AND TRANSFORMING GROWTH FACTOR-β LEVELS IN CHRONIC HEPATITIS C PATIENTS ARE IMMUNOMODULATED BY THERAPY

  2002cites this paper
• An Analysis of Acute Changes in Interleukin-6 Levels After Treatment of Hepatitis C with Consensus Interferon

  2001cites this paper
• Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms.

  2001cites this paper
• Relationship Among Hepatic Inflammatory Changes, Circulating Levels of Cytokines, and Response to IFN-α in Chronic Hepatitis C

  1998cites this paper